128 related articles for article (PubMed ID: 7901893)
21. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.
Gorbach SL; Nahas L; Plaut AG; Weinstein L; Patterson JF; Levitan R
Gastroenterology; 1968 Apr; 54(4):575-87. PubMed ID: 4385122
[No Abstract] [Full Text] [Related]
22. Studies of prostaglandins and sulphasalazine in ulcerative colitis.
Gould SR; Brash AR; Conolly ME; Lennard-Jones JE
Prostaglandins Med; 1981 Feb; 6(2):165-82. PubMed ID: 6113614
[TBL] [Abstract][Full Text] [Related]
23. Extension of ulcerative colitis.
Alkim C; Alkim H; Dağli U; Parlak E; Ulker A; Sahın B
Turk J Gastroenterol; 2011 Aug; 22(4):382-7. PubMed ID: 21948568
[TBL] [Abstract][Full Text] [Related]
24. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy.
Sagawa T; Kakizaki S; Tomizawa T; Nakayama T; Tanaka H; Tojima H; Sato K; Kusano M; Okamura S; Yamada M
Colorectal Dis; 2016 Jul; 18(7):696-702. PubMed ID: 26748553
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with disease evolution in Greek patients with inflammatory bowel disease.
Chatzicostas C; Roussomoustakaki M; Potamianos S; Paspatis G; Mouzas I; Romanos J; Mavrogeni H; Kouroumalis E
BMC Gastroenterol; 2006 Jul; 6():21. PubMed ID: 16869971
[TBL] [Abstract][Full Text] [Related]
26. Biochemical intestinal parameters in germ-free minipigs and rats and in ex-germ-free minipigs and rats monoassociated with Escherichia coli.
Cardona ME; Kozakova H; Collinder E; Persson AK; Midtvedt T; Norin E
J Vet Med A Physiol Pathol Clin Med; 2005 Apr; 52(3):109-13. PubMed ID: 15836440
[TBL] [Abstract][Full Text] [Related]
27. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
28. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
29. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
30. [Intestinal microflora during the treatment of non-specific ulcerative colitis with salasosulfapyridine].
Marko OP; Bronshteĭn AS; Korneva TK
Sov Med; 1972 May; 35(5):86-9. PubMed ID: 4402892
[No Abstract] [Full Text] [Related]
31. Topical therapy is underused in patients with ulcerative colitis.
Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
[TBL] [Abstract][Full Text] [Related]
32. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Regueiro M; Loftus EV; Steinhart AH; Cohen RD;
Inflamm Bowel Dis; 2006 Oct; 12(10):972-8. PubMed ID: 17012968
[TBL] [Abstract][Full Text] [Related]
33. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.
Pitcher MC; Beatty ER; Cummings JH
Gut; 2000 Jan; 46(1):64-72. PubMed ID: 10601057
[TBL] [Abstract][Full Text] [Related]
34. Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.
West B; Lendrum R; Hill MJ; Walker G
Gut; 1974 Dec; 15(12):960-5. PubMed ID: 4155692
[TBL] [Abstract][Full Text] [Related]
35. Clostridium difficile and inflammatory bowel disease.
Greenfield C; Aguilar Ramirez JR; Pounder RE; Williams T; Danvers M; Marper SR; Noone P
Gut; 1983 Aug; 24(8):713-7. PubMed ID: 6135648
[TBL] [Abstract][Full Text] [Related]
36. Occurrence of Clostridium difficile toxin in inflammatory bowel disease.
Rolny P; Järnerot G; Möllby R
Scand J Gastroenterol; 1983 Jan; 18(1):61-4. PubMed ID: 6144171
[TBL] [Abstract][Full Text] [Related]
37. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
Azad Khan AK; Truelove SC
Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro.
Rubinstein A; Das KM; Melamed J; Murphy RA
Clin Exp Immunol; 1978 Aug; 33(2):217-24. PubMed ID: 31252
[TBL] [Abstract][Full Text] [Related]
39. Biochemical intestinal parameters in pigs reared outdoors and indoors, and in germ-free pigs.
Collinder E; Cardona ME; Kozakova H; Norin E; Stern S; Midtvedt T
J Vet Med A Physiol Pathol Clin Med; 2002 May; 49(4):203-9. PubMed ID: 12069263
[TBL] [Abstract][Full Text] [Related]
40. Search for enteric microbial pathogens in patients with ulcerative colitis.
Brown WJ; Hudson MJ; Patrick S; Matthews SC; Hill MJ; Gent AE; Grace RH; Hellier MD; Swarbrick ET
Digestion; 1992; 53(3-4):121-8. PubMed ID: 1363319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
